Quantcast

Latest Cilomilast Stories

2014-04-23 23:04:20

New research report “COPD Drug Market Opportunity & Clinical Pipeline Analysis” worked out by Kuick Research is now available at MarketPublishers.com. According to the study, the world COPD market is predicted to grow at a CAGR of nearly 8% and reach USD 17.5 billion by 2018. London, UK (PRWEB) April 23, 2014 Around 1 billion people across the globe suffer from pulmonary or respiratory diseases. Within the respiratory therapeutic domain, chronic obstructive pulmonary disease...

2011-08-04 06:39:28

(Ivanhoe Newswire)--Physician organizations are announcing new recommendations to consider when diagnosing and treating COPD. Chronic obstructive pulmonary disease (COPD) is a common lung disease that makes it challenging to breathe. Smoking is the leading cause however some people who smoke never develop COPD. Other risk factors to be aware of are exposure to certain gases or fumes, heavy amounts of second hand smoke or pollution, and frequent use of cooking fire without adequate...

2011-05-11 12:19:47

Giving patients with chronic obstructive pulmonary disease (COPD) newly available oral phosphodiesterase 4 (PDE4) inhibitors, roflumilast or cilomilast, improves lung function and reduces the likelihood of a flareup, but does not increase general quality of life. These are the findings of a new systematic review by Cochrane researchers. COPD is one of the leading causes of global morbidity and mortality, resulting in a growing social and economic burden (GOLD 2005). In 2002, research...

2011-01-27 14:41:20

Researchers have proved that a single "master switch" enzyme, known as aldose reductase, is key in producing excess mucous that clogs the airways of people with asthma and chronic obstructive pulmonary disease (COPD). The enzyme's action can be blocked by drugs whose safety has been shown in clinical trials for other diseases "“ a discovery that could improve therapies for the 510 million people worldwide suffering from asthma and COPD. The findings are from a University of Texas...

2010-09-25 11:00:00

PHILADELPHIA, Sept. 25 /PRNewswire/ -- Patients at risk of coronary disease who have reactive airways may breathe easier thanks to new data released today at the 15th Annual Scientific Session of the American Society of Nuclear Cardiology. A new study shows that regadenoson may be safely tolerated by patients with chronic lung disease, providing an alternative to adenosine, which is known to induce brochoconstriction in some patients. This multicenter study included 532 patients with...

2008-11-04 12:00:05

Mpex Pharmaceuticals, a clinical stage biopharmaceutical company, has initiated a Phase II clinical study with MP-376 for use as a maintenance therapy in reducing the incidence of pulmonary exacerbations in patients with chronic obstructive pulmonary disease. MP-376 is the company's novel formulation of levofloxacin inhalation solution. The Phase II, US multi-center randomized, double-blind, placebo-controlled study, Mpex 302 is expected to enroll approximately 300 chronic obstructive...

2008-10-03 12:00:27

REYKJAVIK, Iceland, Oct. 3 /PRNewswire-FirstCall/ -- deCODE genetics today announced the filing of an investigational new drug (IND) application for DG071, the company's novel small-molecule modulator of phosphodiesterase 4 (PDE4), with the US Food and Drug Administration (FDA). The compound is being developed as a new and potentially safer means of targeting PDE4 to combat memory loss and cognitive deficits associated with Alzheimer's disease and other disorders in which neural signaling...

2008-09-24 09:00:48

Osiris Therapeutics, a stem cell therapeutic company, has completed enrollment in a human clinical trial designed to evaluate Prochymal, the company's proprietary formulation of adult mesenchymal stem cells, for the treatment of moderate to severe chronic obstructive pulmonary disease. A total of 62 patients were enrolled in the Phase II trial at six sites throughout the US. Osiris is investigating Prochymal in patients with chronic obstructive pulmonary disease (COPD), reported to be the...

2008-09-22 09:00:12

Dynavax Technologies, Inc. (NASDAQ:DVAX) today announced receipt of a $4.5 million milestone payment from its partner AstraZeneca AB for the nomination of candidate drug AZD1419 for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As part of this potential $136 million development and commercialization collaboration, AstraZeneca and Dynavax have initiated Investigational New Drug (IND) enabling studies with AZD1419 and plan to begin phase 1 clinical development in...

2008-09-03 03:00:05

NEW YORK, Sept. 3 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. and Laboratorios Almirall, S.A. today announced results from two global Phase III studies of aclidinium bromide, a novel long-acting inhaled anticholinergic for the treatment of patients with chronic obstructive pulmonary disease (COPD). In both the ACCLAIM/COPD I&II (AClidinium CLinical Trial Assessing Efficacy and Safety In Moderate to Severe COPD Patients) studies, once-daily aclidinium bromide showed a...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'